Go to forum

Studies / Research overview

GHK-Cu: what 50 years of copper peptide research supports

Strong evidence for skin and wound repair, intriguing gene-expression data, and very little on injection. Where the research on GHK-Cu actually stands.

Published

Summaries of published research for educational discussion. Not medical advice.

GHK-Cu, often just called “copper peptide,” is one of the few research peptides that also sits on drugstore shelves. It’s in serums and creams marketed for firmer skin, and it’s sold as an injectable among research peptides. It also has one of the longest research histories of any peptide in the community’s rotation. Here is what that research does and doesn’t support.

What it is

GHK is a tiny peptide, just three amino acids (glycine, histidine, and lysine), that occurs naturally in human blood plasma, saliva, and urine. It binds copper tightly, and the copper-bound form is GHK-Cu. Researcher Loren Pickart identified it in the 1970s while studying why plasma from younger people affected liver cells differently from plasma from older people. Levels of GHK in plasma fall with age, which is part of why it attracted anti-aging interest.

What the evidence shows

Skin and wound healing: the strongest area. Decades of lab and animal studies show GHK-Cu encourages wound repair. It attracts immune and repair cells, stimulates collagen and other structural components of skin, and supports new blood vessel growth. Small human studies of topical creams have reported improvements in skin firmness, fine lines, and thickness. Those trials are generally short and small, and many were run or funded by companies selling the products.

Gene expression: the most intriguing area. Large gene-expression databases suggest GHK shifts the activity of a surprisingly large number of human genes, many involved in tissue repair, inflammation, and antioxidant defense. In one well-known 2012 study, researchers identified a gene-activity pattern linked to lung tissue destruction in emphysema. When lung cells from patients were exposed to GHK in the lab, that pattern shifted back toward normal, and the cells’ ability to organize structural fibers improved.

Hair: limited. Copper peptides appear in hair-growth products, but the human evidence is thin and mostly small or uncontrolled.

What’s missing

  • No solid human evidence for injection. Nearly all human data involve products applied to the skin. Whether injected GHK-Cu helps with anything, and what its long-term safety looks like, hasn’t been established in controlled trials.
  • Lab results don’t equal clinical results. Shifting gene activity in cells in a dish is a promising signal, not proof of benefit in people.
  • Copper isn’t free of risk. The body tightly regulates copper. Adding more by injection, rather than the tiny amounts absorbed through skin, is a different exposure that hasn’t been well studied.
  • Regulatory status: Injectable GHK-Cu was among 12 peptides the FDA removed from its compounding restricted list in April 2026, but that change alone doesn’t authorize compounding. See our explainer on the 2026 FDA changes. Topical cosmetic use is regulated separately and is widely available.

Bottom line

GHK-Cu has a genuine research base for skin and wound repair, and some of the most interesting gene-expression data of any small peptide. The evidence is strongest for topical use and weakest for injection, which is roughly the opposite of how a lot of people now use it.

Sources